Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observer-blind, Randomized, Active-controlled, Multi-centric Phase III Study to Assess Immunogenicity and Safety of Hexavalent (DTwP-Hepatitis B-IPV-Hib) Vaccine Containing Reduced Dose IPV in Comparison With HEXASIIL®

NCT06413121 is registered in ClinicalTrials.gov with Serum Institute of India Pvt. Ltd. as lead sponsor.

NCT NCT06413121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06413121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observer-blind, Randomized, Active-controlled, Multi-centric Phase III Study to Assess Immunogenicity and Safety of Hexavalent (DTwP-Hepatitis B-IPV-Hib) Vaccine Containing Reduced Dose IPV in Comparison With HEXASIIL®
Lead sponsor
Serum Institute of India Pvt. Ltd.
Phase
Phase 3
Overall status
Completed
Start date
May 9, 2024
Completion date
February 20, 2026
Enrollment
1,557 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

diptheria immunization, haemophilus influenzae type b immunization, hepatitis b immunization, pertussis immunization, polio immunization, tetanus immunization